KRAS and colonic neoplasm: Similarly, in a translational study on PETACC-3, EORTC 40993, and SAKK 60-00 trials of patients with stage II and III resected colon cancer, there was no significant difference in DFS between patients with WT and KRAS mutant tumors, whether unstratified or stratified by stage or MSI status [68].